H.C. Wainwright analyst Patrick Trucchio maintains $Sangamo Therapeutics (SGMO.US)$ with a buy rating, and maintains the target price at $10.
According to TipRanks data, the analyst has a success rate of 35.4% and a total average return of 16.7% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Sangamo Therapeutics (SGMO.US)$'s main analysts recently are as follows:
Following Sangamo's latest quarterly report, there's an anticipation of a significant development pathway for the Fabry program aligned with the FDA. The subsequent discussions centered on the program's future, with partnership negotiations reportedly in the advanced phase. The expectation is set for potentially favorable data outcomes by the third quarter of 2025, followed by anticipated regulatory approval in 2026, and a partnership deal announcement is expected imminently.
The firm anticipates that the formation of partnerships concerning the Fabry program and the comprehensive data from the pivotal study will act as primary catalysts. It is believed that the potential rise in the stock's value will be propelled by the proof of concept for the company's proprietary ZFP transcription factor neurology programs.
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.